EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy

Sihui Yu, Hongyang Xiao, Li Ma, Jiawen Zhang, Jiarong Zhang

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2023-09 · 1878 (5) · 188946

DOI: 10.1016/j.bbcan.2023.188946 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023-09. Verfasst von Sihui Yu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 272 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunogenic cell death (ICD) has been a revolutionary modality in cancer treatment since it kills primary tumors and prevents recurrent malignancy simultaneously. ICD represents a particular form of cancer cell death accompanied by production of damage-associated molecular patterns (DAMPs) that can be recognized by pattern recognition receptors (PRRs), which enhances infiltration of effector T cells and potentiates antitumor immune responses. Various treatment methods can elicit ICD involving chemo- and radio-therapy, phototherapy and nanotechnology to efficiently convert dead cancer cells into vaccines and trigger the antigen-specific immune responses. Nevertheless, the efficacy of ICD-induced therapies is restrained due to low accumulation in the tumor sites and damage of normal tissues. Thus, researchers have been devoted to overcoming these problems with novel materials and strategies. In this review, current knowledge on different ICD modalities, various ICD inducers, development and application of novel ICD-inducing strategies are summarized. Moreover, the prospects and challenges are briefly outlined to provide reference for future design of novel immunotherapy based on ICD effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansImmunogenic Cell DeathPhototherapyImmunotherapy

Stichwörter der Autor:innen

Immunogenic cell deathRegulated cell deathTumor immune microenvironmentTumor-infiltrating lymphocyte

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
  • Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; Reproductive Medicine Center, Department of Obstetrics and Gyne…
  • Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China. Electronic address: zhang.jiarong@zs-hospital.sh.cn.

Förderung

  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Yu, S., Xiao, H., Ma, L., Zhang, J., & Zhang, J. (2023). Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1878(5), 188946. https://doi.org/10.1016/j.bbcan.2023.188946

Vancouver

Yu S, Xiao H, Ma L, Zhang J, Zhang J. Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(5):188946. doi:10.1016/j.bbcan.2023.188946

BibTeX
@article{Yu2023,
  author = {Yu, Sihui and Xiao, Hongyang and Ma, Li and Zhang, Jiawen and Zhang, Jiarong},
  title = {Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2023},
  volume = {1878},
  number = {5},
  pages = {188946},
  doi = {10.1016/j.bbcan.2023.188946}
}
Kostenlos starten →